| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Stemedica Cell Technologies, Inc., a biopharmaceutical company, engages in the development and manufacture of adult stem cells and stem cell factors for research institutions and hospitals for pre-clinical and clinical studies. The company was incorporated in 2005 and is based in San Diego, California with a subsidiary location in Lausanne, Switzerland.
Revolution Health Group LLC is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Virginia Physicians is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PaxeraHealth (Formerly Paxeramed) is a leading healthcare solution developer based in Boston, MA. We develop a full range of medical imaging solutions including PACS, RIS, VNA, multi-modality workstations, mobile App viewers, patient portal, dental PACS, Vet PACS, advanced visualization, Patient engagement and enterprise solutions. Leveraging technology and staying at the forefront of new healthcare IT technological developments is a high priority for PaxeraHealth. The company develops the next generation medical imaging and Patient engagement technologies designed to automate clients` workflow, elevate patient care and cut healthcare costs.